1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.
2. Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia 2014;34:409-425.
3. Westergaard ML, Glumer C, Hansen EH, Jensen RH. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain 2014;155:2005-2013.
4. Granell F, Farina S, Malferrari G, Manzoni GC. Drug abuse in chronic headache a clinico-epidemiologic study. Cephalalgia 1987;7:15-19.
5. Diener H-C, Limmroth V. Medication-overuse headache: a worldwide problem. The Lancet Neurology 2004;3:475-483.
6. Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 2011;31:837-850.
7. Colás R, Muñoz P, Temprano R, Gómez C, Pascual J. Chronic daily headache with analgesic overuse Epidemiology and impact on quality of life. Neurology 2004;62:1338–1342.
8. Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide. BioMed Central, 2015.
9. Feigin VL, Abajobir AA, Abate KH, et al. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Neurology 2017;16:877-897.
10. Rastenytė D, Mickevičienė D, Stovner LJ, Thomas H, Andrée C, Steiner TJ. Prevalence and burden of headache disorders in Lithuania and their public-health and policy implications: a population-based study within the Eurolight project. The journal of headache and pain 2017;18:1-10.
11. Mbewe E, Zairemthiama P, Yeh H-H, Paul R, Birbeck GL, Steiner TJ. The epidemiology of primary headache disorders in Zambia: a population-based door-to-door survey. The journal of headache and pain 2015;16:1-9.
12. Zebenigus M, Tekle-Haimanot R, Worku DK, Thomas H, Steiner TJ. The prevalence of primary headache disorders in Ethiopia. The journal of headache and pain 2016;17:1-9.
13. Manandhar K, Risal A, Steiner TJ, Holen A, Linde M. The prevalence of primary headache disorders in Nepal: a nationwide population-based study. The journal of headache and pain 2015;16:1-10.
14. Steiner TJ, Rao GN, Kulkarni GB, Gururaj G, Stovner LJ. Headache yesterday in Karnataka state, India: prevalence, impact and cost. The journal of headache and pain 2016;17:1-6.
15. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008;71:1821-1828.
16. Saylor D, Steiner TJ. The global burden of headache. Seminars in neurology; 2018: Thieme Medical Publishers: 182-190.
17. Kristoffersen E, Grande R, Aaseth K, Russell M, Lundqvist C. Medication‐overuse headache detoxification reduces headache disability–the Akershus study of chronic headache. European journal of neurology 2018;25:1140-1147.
18. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012;19:703-711.
19. Chen P-K, Wang S-J. Medication overuse and medication overuse headache: risk factors, comorbidities, associated burdens and nonpharmacologic and pharmacologic treatment approaches. Current pain and headache reports 2019;23:1-7.
20. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag Health Studies. Pain 2012;153:56-61.
21. Atasoy HT, Unal AE, Atasoy N, Emre U, Sumer M. Low income and education levels may cause medication overuse and chronicity in migraine patients. Headache: The Journal of Head and Face Pain 2005;45:25-31.
22. Raggi A, Grazzi L, Ayadi R, et al. Clinical and psychosocial features of frequent relapsers (FR) among patients with chronic migraine and medication overuse. Neurological Sciences 2017;38:169-171.
23. Cevoli S, Mochi M, Scapoli C, et al. A genetic association study of dopamine metabolism‐related genes and chronic headache with drug abuse. European Journal of Neurology 2006;13:1009-1013.
24. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener H-C. Features of medication overuse headache following. Neurology 2002;59:1011–1014.
25. Creac'h C, Radat F, Mick G, et al. One or several types of triptan overuse headaches? Headache 2009;49:519-528.
26. Kosinski M, Bayliss M, Bjorner J, et al. A six-item short-form survey for measuring headache impact: The HIT-6™. Quality of life research 2003;12:963-974.
27. Bayliss M, Batenhorst A. The HIT-6™ a user’s guide. Lincoln, RI: QualityMetric Incorporated 2002.
28. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001;56:S20-S28.
29. Kroenke K, Spitzer RL, Williams JB. The PHQ‐9: validity of a brief depression severity measure. Journal of general internal medicine 2001;16:606-613.
30. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine 2006;166:1092-1097.
31. Chu M-k, Im H-j, Ju Y-s, Yu K-h, Ma H-i, Lee B-c. Validity and reliability assessment of Korean headache impact test-6 (HIT-6). 2008.
32. Lee HS, Chung CS, Song HJ, Park HS. The reliability and validity of the MIDAS (Migraine Disability Assessment) Questionnaire for Korean migraine sufferers. Journal of the Korean Neurological Association 2000;18:287-291.
33. Choi HS, Choi JH, Park KH, et al. Standardization of the Korean version of Patient Health Questionnaire-9 as a screening instrument for major depressive disorder. Journal of the Korean Academy of Family Medicine 2007;28:114-119.
34. Seo J-G, Park S-P. Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine. The journal of headache and pain 2015;16:1-7.
35. Bongsebandhu-Phubhakdi S, Srikiatkhachorn A. Pathophysiology of medication-overuse headache: implications from animal studies. Current pain and headache reports 2012;16:110-115.
36. Landy S, Kaniecki R, Taylor F. Supornsilpchai W, le Grand SM, Srikiatkhachorn A. Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia. 2010; 30: 1101-1109. Headache 2011;51.
37. Ayzenberg I, Obermann M, Nyhuis P, et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006;26:1106-1114.
38. Perrotta A, Serrao M, Sandrini G, et al. Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control. Cephalalgia 2010;30:272-284.
39. Coppola G, Currà A, Di Lorenzo C, et al. Abnormal cortical responses to somatosensory stimulation in medication-overuse headache. BMC neurology 2010;10:1-9.
40. Ferraro D, Vollono C, Miliucci R, et al. Habituation to pain in “medication overuse headache”: A CO2 laser‐evoked potential study. Headache: The Journal of Head and Face Pain 2012;52:792-807.
41. Supornsilpchai W, Le Grand SM, Srikiatkhachorn A. Involvement of pro‐nociceptive 5‐HT2A receptor in the pathogenesis of medication‐overuse headache. Headache: The Journal of Head and Face Pain 2010;50:185-197.
42. Reuter U, Salomone S, Ickenstein GW, Waeber C. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia 2004;24:398-407.
43. Dobson C, Tohyama Y, Diksic M, Hamel E. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 2004;24:2–11.
44. Srikiatkhachorn A, Anthony M. Serotonin receptor adaptation in patients with analgesic-induced headache. Cephalalgia 1996;16:419-422.
45. Limmroth V, Kazarawa Z, Fritsche G, Diener H-C. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. The Lancet 1999;353.
46. Bauer MK, Lieb K, Schulze‐Osthoff K, et al. Expression and regulation of cyclooxygenase‐2 in rat microglia. European journal of biochemistry 1997;243:726-731.
47. BB W. Regulation of prostaglandin synthesis in human vascular cells. Ann N Y Acad Sci 1987;509:142–148.
48. Di Lorenzo C, Di Lorenzo G, Sances G, et al. Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism. The journal of headache and pain 2009;10:349-355.
49. Cupini LM, Sarchielli P, Calabresi P. Medication overuse headache: neurobiological, behavioural and therapeutic aspects. Pain 2010;150:222-224.
50. Meng ID, Dodick D, Ossipov MH, Porreca F. Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. Cephalalgia 2011;31:851-860.
51. E.Hyman S, C.Malenka R. Addiction and the brain the neurobiology of compulsion and its persistence. Nature reviews neuroscience 2001;2:695-703.
52. Kristoffersen ES, Lundqvist C. Medication-overuse headache: a review. J Pain Res 2014;7:367-378.
53. Diener H-C. Detoxification for medication overuse headache is not necessary. Cephalalgia 2012;32:423-427.
54. Evers S, Jensen R. Treatment of medication overuse headache–guideline of the EFNS headache panel. European Journal of Neurology 2011;18:1115-1121.
55. Olesen J. Detoxification for medication overuse headache is the primary task. Cephalalgia 2012;32:420-422.
56. Hagen K, Albretsen C, Vilming S, et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia 2009;29:221-232.
57. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 2006;66:1894-1898.
58. Linton-Dahlöf P, Linde M, Dahlöf C. Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication: a retrospective study. Cephalalgia 2000;20:658-662.
59. Sances G, Ghiotto N, Galli F, et al. Risk factors in medication-overuse headache: a 1-year follow-up study (care II protocol). Cephalalgia 2010;30:329-336.
60. Atasoy HT, Atasoy N, Unal AE, Emre U, Sumer M. Psychiatric comorbidity in medication overuse headache patients with pre-existing headache type of episodic tension-type headache. Eur J Pain 2005;9:285-291.
61. Radat F, Creac’h C, Swendsen J, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 2004;25:519–522.